EA202090063A1 - COMPOSITIONS AND METHODS FOR TREATMENT OF TAUPATHIA - Google Patents

COMPOSITIONS AND METHODS FOR TREATMENT OF TAUPATHIA

Info

Publication number
EA202090063A1
EA202090063A1 EA202090063A EA202090063A EA202090063A1 EA 202090063 A1 EA202090063 A1 EA 202090063A1 EA 202090063 A EA202090063 A EA 202090063A EA 202090063 A EA202090063 A EA 202090063A EA 202090063 A1 EA202090063 A1 EA 202090063A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
taupathia
compositions
methods
taupathies
Prior art date
Application number
EA202090063A
Other languages
Russian (ru)
Inventor
Гиридхар Тиручерай
Майкл Франс Берджесс
Масано Тианеси Хуанг
Лори С. Бартон
Юн Цюань
Original Assignee
Бристоль-Мейерз Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристоль-Мейерз Сквибб Компани filed Critical Бристоль-Мейерз Сквибб Компани
Publication of EA202090063A1 publication Critical patent/EA202090063A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

Предложены режимы дозирования и готовые формы антител против тау человека. Такие готовые формы и режимы дозирования находят применение в лечении таупатий, таких как прогрессирующий надъядерный паралич и болезнь Альцгеймера.Dosing regimens and ready-made forms of antibodies against human tau are proposed. Such formulations and dosage regimens find use in the treatment of taupathies such as progressive supranuclear palsy and Alzheimer's disease.

EA202090063A 2017-06-16 2017-06-16 COMPOSITIONS AND METHODS FOR TREATMENT OF TAUPATHIA EA202090063A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/037991 WO2018231254A1 (en) 2017-06-16 2017-06-16 Compositions and methods for treating tauopathies

Publications (1)

Publication Number Publication Date
EA202090063A1 true EA202090063A1 (en) 2020-04-03

Family

ID=59388133

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090063A EA202090063A1 (en) 2017-06-16 2017-06-16 COMPOSITIONS AND METHODS FOR TREATMENT OF TAUPATHIA

Country Status (11)

Country Link
EP (1) EP3638694A1 (en)
JP (2) JP2020529394A (en)
KR (1) KR20200018502A (en)
CN (1) CN110770253A (en)
AU (1) AU2017418317A1 (en)
BR (1) BR112019026298A2 (en)
CA (1) CA3064550A1 (en)
EA (1) EA202090063A1 (en)
IL (1) IL271256A (en)
MX (1) MX2019015071A (en)
WO (1) WO2018231254A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014248515B2 (en) 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
ES2933491T3 (en) 2016-05-02 2023-02-09 Prothena Biosciences Ltd tau immunotherapy
KR102471787B1 (en) 2016-05-02 2022-11-29 프로테나 바이오사이언시즈 리미티드 Tau recognition antibody
EP3583123A1 (en) 2017-02-17 2019-12-25 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
CA3061516A1 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
WO2020180819A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
CA3227440A1 (en) 2021-07-27 2023-02-02 Stand Therapeutics Co., Ltd. Peptide tag and nucleic acid encoding same
KR20230172262A (en) 2022-06-15 2023-12-22 재단법인대구경북과학기술원 Composition for preventing or treating tauopathy comprising PTK2 inhibitor as an active ingredient

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
BRPI0917888A2 (en) * 2008-09-19 2014-02-25 Pfizer STABLE NET ANTIBODY FORMULATION
JP2014503178A (en) * 2010-10-11 2014-02-13 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー Human anti-tau antibody
JP5941770B2 (en) 2012-06-28 2016-06-29 株式会社ミマキエンジニアリング Ink jet recording apparatus, liquid supply apparatus, and recording head cleaning method
MX359817B (en) * 2012-08-16 2018-10-11 Ipierian Inc Methods of treating a tauopathy.
PL3007726T3 (en) * 2013-06-10 2021-01-11 Ipierian, Inc. Methods of treating a tauopathy
JP6629201B2 (en) * 2013-11-27 2020-01-15 アイピエリアン，インコーポレイティド How to treat tauopathy
RU2017111228A (en) * 2014-10-18 2018-11-21 Пфайзер Инк. Anti-IL-7R Antibody Compositions

Also Published As

Publication number Publication date
KR20200018502A (en) 2020-02-19
IL271256A (en) 2020-01-30
EP3638694A1 (en) 2020-04-22
JP2020529394A (en) 2020-10-08
WO2018231254A1 (en) 2018-12-20
JP2022033757A (en) 2022-03-02
BR112019026298A2 (en) 2020-07-14
MX2019015071A (en) 2020-02-13
CN110770253A (en) 2020-02-07
CA3064550A1 (en) 2018-12-20
AU2017418317A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
EA202090063A1 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF TAUPATHIA
CY1122265T1 (en) ANTIBODIES AGAINST THEM AND THEIR USES
MX2022001755A (en) Cyclic di-nucleotide compounds and methods of use.
EA201891186A1 (en) ANTIBODIES, NEUTRALIZING THE VIRUS OF HUMAN IMMUNODEFICIENCY
MX2019007587A (en) Ophthalmic composition for treatment of dry eye disease.
EA201790273A1 (en) FLAGELLIN COMPOSITIONS AND THEIR APPLICATION
EA201691853A1 (en) AGONISTS OF MUSCARINE RECEPTORS
EA201791733A1 (en) Derivatives of 9H-pyrrolodipyridine
EA201991447A1 (en) VISCOSITY REDUCTION OF PHARMACEUTICAL COMPOSITIONS
EA201991029A1 (en) MAGL INHIBITORS
EA201891609A1 (en) DERIVATIVES 3 - ((HETERO-) ARYL) ALKYL-8-AMINO-2-OXO-1,3-DIAZASPIRO [4.5] DECANE
MX2022002635A (en) Angiopoietin-like 4 antibodies and methods of use.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201891610A1 (en) DERIVATIVES 3- (CARBOXYETHYL) -8-AMINO-2-OXO-1,3-DIAZASPIRO [4.5] DEAN
EA201892443A1 (en) PHARMACEUTICAL COMPOSITIONS AND DOSING MODES FOR CLINICAL USE OF ANTIBODIES AGAINST ANTIGEN 2 DENDRITIC BLOOD CELLS
EA202190281A1 (en) DERIVATIVES 3 - ((HETERO-) ARYL) -8-AMINO-2-OXO-1,3-DIAZA-SPIRO [4,5] DECANE
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
EA201892376A1 (en) COMBINED COMPOSITION OF THREE ANTI-VIRUS COMPOUNDS
EA202191515A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING APIXABAN
CO2018011420A2 (en) Liquid phosphaplatin formulations
EA202192532A1 (en) MIRIKIZUMAB FOR USE IN THE TREATMENT OF CROHN'S DISEASE
JOP20190286A1 (en) Compositions and methods for treating tauopathies
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
EA201990261A1 (en) 2,5-DUB-SUBSTITUTED 3-METHYL-PYRASINES and 2,5,6-triple-substituted 3-METHYL-PYRASINES AS SHP2 ALLOSTERIC INHIBITORS
EA202090512A1 (en) Pyrazolopyrimidinone compounds and their use